{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-036588","form_type":"8-K","ticker":null,"cik":"0001445499","company_name":"IMPEL PHARMACEUTICALS INC","filed_at":"2024-02-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.214767+00:00","generated_at":"2026-06-06T02:13:15.661588+00:00","sec_items":["1.01","2.01","1.03","5.02"],"event_type":"m_and_a","sentiment":"negative","materiality_score":1.0,"calibrated_materiality_score":1.0,"confidence":"high","headline":"Impel completes asset sale to JN Bidco for $17.5M cash; CEO departs","bullets":["Closed sale of substantially all assets to JN Bidco LLC for $17.5M upfront cash plus contingent earnout based on net sales/licensing fees.","Len Paolillo resigned as Interim CEO effective Feb 12, 2024; entered consulting agreement at $500/hr through June 30, 2024.","Company remains in Chapter 11; stock delisted from Nasdaq, trades on OTC Pink under IMPLQ."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-036588","json":"https://secwatch.observer/filing/0001193125-24-036588.json","markdown":"https://secwatch.observer/filing/0001193125-24-036588.md","text":"https://secwatch.observer/filing/0001193125-24-036588.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1445499/000119312524036588/0001193125-24-036588-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1445499/000119312524036588/d769501d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T02:13:15.661588+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"aacde29179","claim":"Len Paolillo resigned as Interim Chief Executive Officer at IMPEL PHARMACEUTICALS INC.","evidence_excerpt":"Len Paolillo departed as the Company’s Interim Chief Executive Officer on February 12, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1445499/000119312524036588/0001193125-24-036588-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Interim Chief Executive Officer"}],"fact_type":"executive_change"},{"claim_id":"077805d1d4bc531f8b72726846df2c7000c7cb34","claim":"IMPEL PHARMACEUTICALS INC completed a disposition involving JN Bidco LLC for $17,500,000 in cash at the closing of the transactions and (ii) an additional amount in cash based on certain net sales and licensing fees generated by certain (closed 2024-02-12).","evidence_excerpt":"Horse APA ”) with JN Bidco LLC (the “ Bidder ”) to sell substantially all of the assets of the Company (the “ Company Assets ,” and such sale, the “ Asset Sale ”) for (i) $17,500,000 in cash at the closing of the transactions and (ii) an additional amount in cash based on certain net sales and licensing fees generated by certain of the Company Assets, subject","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1445499/000119312524036588/0001193125-24-036588-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"disposition"},{"label":"Counterparty","value":"JN Bidco LLC"},{"label":"Consideration","value":"$17,500,000 in cash at the closing of the transactions and (ii) an additional amount in cash based on certain net sales and licensing fees generated by certain"},{"label":"Closing","value":"2024-02-12"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}